高强度聚焦超声单用或联合TACE治疗不适合肝切除与射频消融的肝细胞癌:II期临床试验
结果显示2年局部控制率73.0%、2年无进展生存率29.7%、2年总生存率70.3%,常见不良事件为肝酶升高、疲劳和疼痛,无4级不良事件或死亡。
要点
- HIFU单用或联合TACE对不适合肝切除和射频消融的HCC患者安全可行。
- 2年局部控制率73.0%,2年总生存率70.3%,中位总生存24个月。
- 年龄、Child-Pugh分级和肿瘤数目是PFS独立预后因素。
核心结论
- HIFU单用或联合TACE治疗安全,能获得较好的局部控制率和相当好的预后。
- 该治疗应考虑用于被判定不适合其他局部治疗的患者。
研究设计与样本
- II期临床试验,纳入20至80岁、有1-3个HCC病灶、无肝外转移证据的原发或复发性肝病变患者。
- 患者接受超声引导下HIFU单用或HIFU联合TACE(TACE在HIFU前4周内进行一次)。
主要发现
- 2年局部控制率为73.0%,中位局部控制时间为22个月。
- 2年无进展生存率为29.7%,中位无进展生存时间为9个月。
- 2年总生存率为70.3%,中位总生存时间为24个月。
- 最常见不良事件为肝酶升高,其次为疲劳和疼痛,无4级不良事件或死亡发生。
- 多因素分析显示年龄、Child-Pugh分级和肿瘤数目是PFS的独立预后因素,AFP水平和肿瘤数目与OS显著相关。
临床怎么用
- 对于不适合肝切除和射频消融的HCC患者,可考虑HIFU单用或联合TACE作为局部治疗选择。
- 治疗前应评估年龄、Child-Pugh分级、肿瘤数目和AFP水平以辅助预后判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: This study aims to evaluate the efficacy and safety of high-intensity focused ultrasound (HIFU) alone or combined with transcatheter arterial chemoembolization (TACE) for patients with hepatocellular carcinoma (HCC) but were contraindicated for hepatectomy and radiofrequency ablation (RFA). METHODS: Patients between 20 and 80 years of age with 1-3 foci of HCC were selected. Included patients have had primary or recurrent liver lesions with no evidence of extra-hepatic metastasis prior to the study. Patients were treated with ultrasound-guided HIFU alone or HIFU combined with TACE (treated with TACE once within 4 weeks prior to receiving HIFU). RESULTS: Thirty-seven patients were enrolled, for a total of 45 lesions. The 2-year local control (LC) rate was 73.0% and the median LC time was 22 months. The 2-year progression-free survival (PFS) was 29.7% and the median PFS time was 9 months. Finally, the 2-year overall survival (OS) was 70.3%, and the median OS time was 24 months. The most common adverse events (AEs) were elevated liver enzymes, followed by fatigue, and pain, no grade 4 AEs or death occurred. Multivariate analysis showed that age, Child-Pugh class, and the number of tumors were independent prognostic factors for PFS and that the AFP levels and the number of tumors were significantly correlated with the OS. CONCLUSIONS: This study indicates that the HIFU/HIFU combined with TACE treatment is safe, and is capable of achieving both a good LC rate and a considerably good prognosis. The procedure should be considered for patients who were deemed unsuitable for other local treatments.
引用
- Gu L, Shen Z, Ji L, et al. High-intensity focused ultrasound alone or combined with transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with unsuitable indications for hepatectomy and radiofrequency ablation: a phase II clinical trial. Surg Endosc. 2021. PMID: 33788029. doi:10.1007/s00464-021-08465-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。